drugset
drugset / Trial / NCT05367778

Phase 1/2 Study of HS-10370 in Patients with Advanced Solid Tumors

NCT05367778 ↗

Phase 1/2 Recruiting 176 enrolled Jiangsu Hansoh Pharmaceutical Co., Ltd.
Non-randomizedSequentialOpen-labelTreatment

Summary

HS-10370 is an oral, highly selective, small molecular inhibitor of KRAS G12C. This study will evaluate the safety, tolerability, pharmacokinetics and clinical activity of HS-10370 in Chinese advanced solid tumor patients.

Timeline

Start
2022-06-03
Primary completion
2025-04-30
Completion
2026-04-30

Drugs

EvaluationDrugModalityDoseRoute
Subject HS-10370 Small molecule — Oral

Indications

neoplasm